Innovator’s Pitch Challenge Waitlist Opens

3 Nov

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

The Innovator’s Pitch Challenge (IPC) taking place on January 10, as a part of the RESI San Francisco at JPM event is now accepting applications to its waiting list. This year’s pent-up demand for face-to-face partnering is a trend we’ve seen throughout 2022, and most notably at RESI Boston in September. The IPC is a popular feature of RESI, and we are thrilled that, due to high demand, we are now accepting waitlist applications. Don’t miss out on the opportunity to attend LSN’s flagship event of the year, RESI San Francisco, during the biggest partnering week in the life sciences industry. The game is afoot!

Apply-for-the-IPC-Waitlist

RESI-Nov-2022-Banner-500H-11032022
RESI-SF-2023-Banner-1100px-11032022

Virtual Partnering at Digital RESI November

3 Nov

By Aidan Eustace, Investor Research Analyst, LSN

AidanIn just over two-weeks, RESI returns for virtual partnering at Digital RESI November. Investors and strategic partners – including large pharma, family offices, and traditional VCs – have been registering daily to attend this partnering-only event November 15-16, and we expect over 150+ investors to participate.

Get to know the investors at Digital RESI November and check out some of the attending firms below. Sign up now for Digital RESI November and bundle your registration with a pass to the hybrid RESI JPM San Francisco, January 10-12 to save $500.

Confirmed Digital RESI November 2022 Investors and Strategic Partners

As of 11/3

Investor-Logos-10312022

RESI-Nov-2022-Banner-500H-11032022
RESI-SF-2023-Banner-1100px-11032022

The Power of an Evolving Pitch

3 Nov

By Karen Deyo, Director of Investor Research, Israel BD, LSN

The RESI conference schedule is based on the reality that startups need to connect with investors multiple times over the course of a year to build and maintain relationships to close fundraising deals. The power of RESI is not just in the chance to meet with an ever-rotating list of new and familiar faces, but also to gauge the traction of your pitch as your company grows and develops.

A company’s pitch is always evolving – as you advance and achieve milestones, necessary pivots, and strategy changes based on your product development, you hone your story. As your story shifts, you start the process anew to find what message resonates the most with your investor audience. As frustrating as it may seem, attending frequent events and taking as many meetings as possible is a necessary step to gaining valuable feedback, as well as allowing you to close your deals.

Digital RESI, November 15-16, is focused entirely on virtual partnering – register today to request meetings with these investors  to make connections. RESI JPM is just around the corner, Life Science Nation (LSN)’s biggest event of the year – don’t miss out on your chance to hone your pitch before then!

Register-now-button-new

RESI-Nov-2022-Banner-500H-11032022
RESI-SF-2023-Banner-1100px-11032022

Hot Investor Mandate: Major Conglomerate Affiliated I-Bank Invests in Privately Owned and Publicly Traded Companies Across All Life Science Sectors Globally

3 Nov

A premier investment bank affiliated with a major conglomerate has an investment arm that invests across public, private, and mezzanine asset classes across various industries, including life sciences and healthcare. The firm is stage agnostic, but has invested in pre-Series A and Series A rounds and has an increased interest in early-stage technologies. Investments can be made out of the firms’ proprietary capital or through special purpose vehicles (SPVs). The firm is interested in global opportunities.

The firm is interested in all healthcare verticals: therapeutics, life science tools and diagnostics, medical devices, and digital health.  Within therapeutics, the firm is open to all types of modalities, indications, and therapeutic classes. The firm is stage agnostic and has invested in all rounds from pre-A to crossover rounds.

The firm has no specific company or management requirements. The firm can act as either lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Western-Europe Based VC Firm Invests Up to €8M in Seed to Series A Round Companies, Including Pre-Clinical Therapeutics, Devices, Digital Health, and More

3 Nov

A firm based in Western Europe invests in early stage companies in the life sciences and Information Technology Sectors. The firm also invests in public companies through Convertible Bonds and secondary alternative markets. The firm also offers Venture Debt financing for private companies. Within Life Sciences, the firm invests in rounds of EUR 2-8 Million Seed and Series A rounds. The firm invests in Europe and North America.

In the life sciences, the firm focuses on therapeutics and also CDMOs, medical devices, healthcare and Digital Health. In therapeutics, the firm focuses on preclinical opportunities with a focus on assets that are 12-18 months prior to IND. Outside of Therapeutics, the firm invests in companies that are revenue positive. The firm generally does not invest in large indication areas such as diabetes, metabolic disease, cardiovascular and renal disease. The firm’s areas of interest include oncology, CNS, dermatology, and ophthalmology (particularly front of eye diseases). The firm has invested in rare diseases but it is not the firm’s sole focus.

In therapeutic opportunities, The firm seeks companies that have obtained proof of concept data in animal studies and can reach human clinical trials with financial needs of up to EUR 8 million to reach a human Proof of Efficacy. In Spain, the firm typically leads investment rounds, and may syndicate with other firms or leverage public funding. In North America, The firm seeks to co-invest in rounds led by top-tier Venture Capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Investment Fund Allocates $1-5M in Early Stage Companies With USA Focus, Most Interested in Therapeutics and Diagnostics Sectors

3 Nov

A venture capital firm founded in 2016 and is headquartered in the USA is currently on their second fund, and the typical check size is flexible, with a typical first check for coming at the seed through series A stage between $1M-5M. The firm is open to both leading or following the investments, but prefers to lead at the seed stage.  The firm focuses on companies located in the US.

The firm is looking for new investment opportunities in sectors focused on applied biology and chemistry, including the therapeutics and diagnostics sectors as well as sustainability, synthetic biology, agtech, and other industrial sectors. The firm is opportunistic in terms of sub-sectors and indications, including all phases of development for therapeutics and various use-cases of synthetic biology. The firm is not typically interested in healthcare services or healthcare IT.

The firm invests in companies in the US and likes to see second or third time entrepreneurs, however the firm will back bold first time entrepreneurs with compelling technologies. The firm is open to both leading or following the investment, and could seek a board seat in certain deals.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Global Life Sciences Research Tools Manufacturer Strategically Invests and Partners With Companies that Fit Their Existing Product Portfolio

3 Nov

A life science research tools manufacturer based in Western Europe with offices worldwide is interested in partnering with companies developing cutting-edge products that are a strategic fit for the firm’s portfolio. The firm is looking for novel product line addition opportunities globally and possible investments in early stage companies located in North America or Europe who are pursuing technology-leading approaches in the firm’s selected application fields.

The firm is focused on investing in companies that are developing products used in research labs, including consumables, bioprocess and lab automation equipment, and digital tools used by research scientists. The firm generally invests in companies with products that are at the commercial stage. The firm is targeting emerging, non-public companies who are pursuing applications in the areas of Molecular Biology, AI/Digital and Cell Biology.

The firm is flexible about partnering structure and open to a range of approaches including licensing, co-development, equity investments and acquisitions. The firm is a first-for-the-company, corporate venture fund with a charter towards select, new business line-directed equity investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →